Integrating costimulatory agonists to optimize immune-based cancer therapies

Immunotherapy

Volumn 1, Issue 2, 2009, Pages 249-264

  Pardee, Angela D ^a   Wesa, Amy K ^a   Storkus, Walter J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Combinational therapeutics; Costimulation; Cytotoxic T cell; Immunotherapy; Regulatory T cell; T cell; TNF receptor

Indexed keywords

4 1BB RECEPTOR AGONIST; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BMS 663513; CD134 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD137 LIGAND FC FUSION PROTEIN; CD28 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR AGONIST; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR LIGAND FC FUSION PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY 4 1BB; MONOCLONAL ANTIBODY GITR; MONOCLONAL ANTIBODY OX40; OX40 LIGAND; OX40 LIGAND RECEPTOR AGONIST; OX40 LIGAND VACCINE; RECOMBINANT CD137 ANTIGEN; RECOMBINANT OX40 FC FUSION PORTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS VECTOR;

BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; CHEMOTHERAPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE THERAPY; GLIOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; IMMUNOBIOLOGY; KIDNEY CARCINOMA; LUNG CARCINOMA; LYMPHOMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIOTHERAPY; REGULATORY T LYMPHOCYTE; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 77953465499     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.2.249     Document Type: Review

References (157)

1. Boon T, Coulie PG, Van den Eynde BJ et al.: Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208 (2006).
2. Dunn GP, Old LJ, Schreiber RD, Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
3. Gajewski TF, Meng Y, Blank C et al.: Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131-145 (2006).
4. Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16, 3-15 (2006).
5. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 169, 1042-1049 (1970).
6. Jenkins MK, Schwartz RH: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319 (1987).
7. Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68 (2005). ■■ Comprehensive review of costimulatory TNF-receptor signaling in normal, pathologic and therapeutic immune responses.
8. Chattopadhyay K, Ramagopal UA, Brenowitz M, Nathenson SG, Almo SC: Evolution of GITRL immune function: murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily. Proc. Natl Acad. Sci. USA 105, 635-640 (2008).
9. Zhou Z, Song X, Berezov A et al.: Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc. Natl Acad. Sci. USA 105, 5465-5470 (2008).
10. Kim DH, Chang WS, Lee YS et al.: 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J. Immunol. 180, 2062-2068 (2008).
11. Wilcox RA, Chapoval AI, Gorski KS et al.: Cutting edge: Expression of functional CD137 receptor by dendritic cells. J. Immunol. 168, 4262-4267 (2002).
12. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16, 311-323 (2002).
13. Dawicki W, Bertram EM, Sharpe AH, Watts TH: 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J. Immunol. 173, 5944-5951 (2004).
14. Lee SW, Park Y, Song A, Cheroutre H, Kwon BS, Croft M: Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J. Immunol. 177, 4464-4472 (2006).
15. Cannons JL, Lau P, Ghumman B et al.: 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167, 1313-1324 (2001). (Pubitemid 32703127)
16. Wen T, Bukczynski J, Watts TH: 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J. Immunol. 168, 4897-4906 (2002). (Pubitemid 34495951)
17. + cytolytic T lymphocytes in vivo. Blood 103, 177-184 (2004). (Pubitemid 38029936)
18. Sabbagh L, Snell LM, Watts TH: TNF family ligands define niches for T cell memory. Trends Immunol. 28, 333-339 (2007). (Pubitemid 47077923)
19. + T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J. Immunol. 169, 4882-4888 (2002).
20. Takahashi C, Mittler RS, Vella AT: Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162, 5037-5040 (1999). (Pubitemid 29307099)
21. Zhu Y, Zhu G, Luo L et al.: CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109, 4882-4889 (2007). (Pubitemid 46827785)
22. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL: Multi-layered action mechanisms of CD137 (4-1 BB)-targeted immunotherapies. Trends Pharmacol. Sci. 29, 383-390 (2008).
23. Myers LM, Vella AT: Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol. 26, 440-446 (2005).
24. + T cells. Blood 105, 2206-2213 (2005). (Pubitemid 40731814)
25. + subsets via CD137 in Type 1 diabetes. Diabetes 56, 186-196 (2007).
26. Myers L, Takahashi C, Mittler RS et al.: Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc. Natl Acad. Sci. USA 100, 5348-5353 (2003).
27. + T cells. J. Leukoc. Biol. 75, 785-791 (2004).
28. + T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J. Immunol. 179, 7295-7304 (2007).
29. Hippen KL, Harker-Murray P, Porter SB et al.: Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112, 2847-2857 (2008).
30. Taraban VY, Rowley TF, O'Brien L et al.: Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 32, 3617-3627 (2002).
31. Ma BY, Mikolajczak SA, Danesh A et al.: The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells. Blood 106, 2002-2010 (2005).
32. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M: The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165, 3043-3050 (2000). (Pubitemid 30728154)
33. + T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with alphaCTLA-4. J. Immunol. 167, 6804-6811 (2001).
34. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M: Costimulation of CD8 T cell responses by OX40. J. Immunol. 172, 4821-4825 (2004). (Pubitemid 38456404)
35. Prell RA, Evans DE, Thalhofer C, Shi T, Funatake C, Weinberg AD: OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. J. Immunol. 171, 5997-6005 (2003).
36. Bansal-Pakala P, Jember AG, Croft M: Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7, 907-912 (2001).
37. Graham DS, Graham RR, Manku H et al.: Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat. Genet. 40, 83-89 (2008).
38. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M: The costimulation-regulated duration of PKB activation controls T cell longevity. Nat. Immunol. 5, 150-158 (2004).
39. + memory T cell survival and significantly increases recall responses. Eur. J. Immunol. 37, 157-166 (2007).
40. Lee SJ, Rossi RJ, Lee SK et al.: CD134 costimulation couples the CD137 pathway to induce production of supereffector CD8 T cells that become IL-7 dependent. J. Immunol. 179, 2203-2214 (2007).
41. + T cells. J. Immunol. 181, 5990-6001 (2008).
42. + T cells. J Immunol. 179, 5014-5023 (2007).
43. So T, Lee SW, Croft M: Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 19, 253-262 (2008).
44. + Tregs. Blood 110, 2501-2510 (2007).
45. Takeda I, Ine S, Killeen N et al.: Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 172, 3580-3589 (2004). (Pubitemid 38337939)
46. + T cells. J. Immunol. 179, 1427-1430 (2007).
47. + regulatory T cells. Nat. Immunol. 4, 330-336 (2003).
48. Ito T, Wang YH, Duramad O et al.: OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl Acad. Sci. USA 103, 13138-13143 (2006).
49. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3, 135-142 (2002).
50. Wu Y, Borde M, Heissmeyer V et al.: FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375-387 (2006). (Pubitemid 44092960)
51. Zhan Y, Gerondakis S, Coghill E et al.: Glucocorticoid-induced TNF receptor expression by T cells is reciprocally regulated by NF-κB and NFAT. J. Immunol. 181, 5405-5413 (2008).
52. + T cells. J. Immunol. 172, 7306-7314 (2004).
53. Ronchetti S, Zollo O, Bruscoli S et al.: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur. J. Immunol. 34, 613-622 (2004).
54. + T cell activation and experimental autoimmune encephalomyelitis. J. Immunol. 172, 4686-4690 (2004).
55. Esparza EM, Arch RH: Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation. J. Immunol. 174, 7869-7874 (2005).
56. Ronchetti S, Nocentini G, Riccardi C, Pandolfi PP: Role of GITR in activation response of T lymphocytes. Blood 100, 350-352 (2002). (Pubitemid 35177469)
57. + T cells. J. Immunol. 173, 5008-5020 (2004).
58. Ji HB, Liao G, Faubion WA et al: Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J. Immunol. 172, 5823-5827 (2004). (Pubitemid 38621178)
59. + T cells. Biochem. Biophys. Res. Commun. 369, 1134-1138 (2008).
60. 5+ regulatory T cells. J. Leukoc. Biol. 82, 93-105 (2007).
61. + regulatory T cells. Proc. Natl Acad. Sci. USA 105, 9331-9336 (2008).
62. Shevach EM, Stephens GL: The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat. Rev. Immunol. 6, 613-618 (2006).
63. Liu B, Li Z, Mahesh SP et al.: Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis. J. Biol. Chem. 283, 8202-8210 (2008).
64. Hanabuchi S, Watanabe N, Wang YH et al.: Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 107, 3617-3623 (2006).
65. Kim HJ, Kim HY, Kim BK, Kim S, Chung DH: Engagement of glucocorticoid-induced TNF receptor costimulates NKT cell activation in vitro and in vivo. J. Immunol. 176, 3507-3515 (2006).
66. Melero I, Shuford WW, Newby SA et al.: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682-685 (1997). ■ First use of agonist modalities targeting 4-1BB, OX40 or glucocorticoid-induced TNF receptor in murine tumor models.
67. Kim JA, Averbook BJ, Chambers K et al.: Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res. 61, 2031-2037 (2001).
68. Miller RE, Jones J, Le T et al.: 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169, 1792 - 1800 (2002).
69. Ito F, Li Q, Shreiner AB et al.: Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64, 8411-8419 (2004). (Pubitemid 39491781)
70. Zhang N, Sadun RE, Arias RS et al.: Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin. Cancer Res. 13, 2758-2767 (2007).
71. Murillo O, Arina A, Hervas-Stubbs S et al.: Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin. Cancer Res. 14, 6895-6906 (2008).
72. Wilcox RA, Flies DB, Wang H et al.: Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-γ despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. Cancer Res. 62, 4413-4418 (2002).
73. Ye Z, Hellstrom I, Hayden-Ledbetter M et al.: Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat. Med. 8, 343-348 (2002).
74. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190, 167-172 (1998).
75. + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. 169, 4230-4236 (2002). (Pubitemid 35178194)
76. Yi KH, Nechushtan H, Bowers WJ et al.: Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Res. 67, 10027-10037 (2007). (Pubitemid 47621254)
77. + T cells. Cancer Res. 62, 3459-3465 (2002).
78. Li B, Lin J, Vanroey M et al.: Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin. Immunol. 125, 76-87 (2007).
79. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594 (1998).
80. Kalinski P, Giermasz A, Nakamura Y et al.: Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol. Immunol. 42, 535-539 (2005).
81. Fallarino F, Gajewski TF: Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J. Immunol. 163, 4109-4113 (1999).
82. Nakajima C, Uekusa Y, Iwasaki M et al.: A role of interferon-γ (IFN-γ) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ-deficient mice. Cancer Res. 61, 3399-3405 (2001).
83. + T cells and inhibit tumor growth in mice. J. Clin. Invest. 118, 376-386 (2008). ■ Oligonucleotide-based 4-1BB agonist therapy as a potentially safer and more cost-effective therapy option versus conventional antibody-based therapies.
84. Yang S, Yang Y, Raycraft J et al.: Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137. Proc. Natl Acad. Sci. USA 101, 4990-4995 (2004).
85. Martinet O, Ermekova V, Qiao JQ et al.: Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J. Natl. Cancer Inst. 92, 931-936 (2000).
86. Chen SH, Pham-Nguyen KB, Martinet O et al.: Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2, 39-46 (2000).
87. Pan PY, Gu P, Li Q et al.: Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J. Immunol. 172, 4779-4789 (2004).
88. + T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int. J. Cancer 109, 499-506 (2004).
89. Tirapu I, Arina A, Mazzolini G et al.: Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int. J. Cancer 110, 51-60 (2004). (Pubitemid 38507203)
90. Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH: The systemic administration of Ig-4-lBB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther. 12, 1526-1533 (2005). (Pubitemid 41508678)
91. McMillin DW, Hewes B, Gangadharan B et al.: Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. Hum. Gene Ther. 17, 798-806 (2006).
92. Shi W, Siemann DW: Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res. 26, 3445-3453 (2006).
93. Ju SA, Cheon SH, Park SM et al.: Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int. J. Cancer 122, 2784-2790 (2008).
94. Kim YH, Choi BK, Kim KH, Kang SW, Kwon BS: Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res. 68, 7264-7269 (2008).
95. Uno T, Takeda K, Kojima Y et al.: Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12, 693-698 (2006). ■ Combinational regimen incorporating three monoclonal antibodies to simultaneously induce tumor cell death and to stimulate the resultant antitumor adaptive immune response.
96. Teng MW, Westwood JA, Darcy PK et al.: Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res. 67, 7495-7504 (2007).
97. Kudo-Saito C, Hodge JW, Kwak H et al.: 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 24, 4975-4986 (2006). (Pubitemid 43782689)
98. Kocak E, Lute K, Chang X et al.: Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66, 7276-7284 (2006).
99. Hirano F, Kaneko K, Tamura H et al.: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089-1096 (2005).
100. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S: Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60, 5514-5521 (2000). (Pubitemid 30761266)
101. Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S: Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 167, 6669-6677 (2001).
102. Andarini S, Kikuchi T, Nukiwa M et al.: Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 64, 3281-3287 (2004). (Pubitemid 38581434)
103. Ali SA, Ahmad M, Lynam J et al.: Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 22, 3585-3594 (2004). (Pubitemid 39099634)
104. + Th cell antitumor immunity in mice. J. Clin. Invest. 117, 3330-3338 (2007).
105. Sadun RE, Hsu WE, Zhang N et al.: Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J. Immunother. 31, 235-245 (2008).
106. Piconese S, Valzasina B, Colombo MP: OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205, 825-839 (2008).
107. Pan PY, Zang Y, Weber K, Meseck ML, Chen SH: OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 6, 528-536 (2002).
108. Song A, Song J, Tang X, Croft M: Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals. Eur. J. Immunol. 37, 1224-1232 (2007).
109. + T cell tolerance to an endogenous tumor antigen. J. Immunol. 176, 974-983 (2006). ■■ Utilizes a translational tumor model to demonstrate the synergistic enhancement of tumor-specific vaccination by OX40 agonist treatment.
110. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD: OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68, 5206-5215 (2008).
111. Morris A, Vetto JT, Ramstad T et al.: Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res. Treat. 67, 71-80 (2001).
112. Weinberg AD, Rivera MM, Prell R et al.: Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164, 2160-2169 (2000).
113. Ruby CE, Montier R, Zheng R, Shu S, Weinberg AD: IL-12 is required for anti-OX40-mediated CD4 T cell survival. J. Immunol. 180, 2140-2148 (2008).
114. Yokouchi H, Yamazaki K, Chamoto K et al.: Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci. 99, 361-367 (2008).
115. Lee SJ, Myers L, Muralimohan G et al.: 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J. Immunol. 173, 3002-3012 (2004). (Pubitemid 39142005)
116. Cuadros C, Dominguez AL, Lollini PL et al.: Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int. J. Cancer 116, 934-943 (2005). (Pubitemid 41209201)
117. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D et al.: Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 176, 6434-6442 (2006).
118. + regulatory T cells. J. Exp. Med. 202, 885-891 (2005).
119. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J. Immunol. 179, 7365-7375 (2007). ■ One of few studies to investigate the role of effector T cells in the GITR-dependent augmentation of antitumor immunity.
120. Hu P, Arias RS, Sadun RE et al.: Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin. Cancer Res. 14, 579-588 (2008).
121. Calmels B, Paul S, Futin N, Ledoux C, Stoeckel F, Acres B: Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther. 12, 198-205 (2005). (Pubitemid 40205100)
122. Ko HJ, Kim YJ, Kim YS et al.: A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67, 7477-7486 (2007).
123. Zhang H, Merchant MS, Chua KS et al.: Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol. Ther. 2, 579-586 (2003).
124. Wan YL, Zheng SS, Zhao ZC et al.: Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity. World J. Gastroenterol. 10, 195-199 (2004).
125. Stephan MT, Ponomarev V, Brentjens RJ et al.: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440-1449 (2007). ■■ Novel combinational approach integrating adoptive T-cell transfer and TNF-receptor-based therapies as a prelude to clinical translation.
126. Son JH, Lee UH, Lee JJ et al.: Humanization of agonistic anti-human 4-1BB monoclonal antibody using a phage-displayed combinatorial library. J. Immunol. Methods 286, 187-201 (2004).
127. Logan T, Hodi F, Margolin K et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer. Presented at: International Society for Biological Therapy of Cancer 23rd Annual Meeting. San Diego, CA, USA, 31 October-2 November (2008).
128. Ramstad T, Lawnicki L, Vetto J, Weinberg A: Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am. J. Surg. 179, 400-406 (2000).
129. Imura A, Hori T, Imada K et al.: OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Blood 89, 2951-2958 (1997).
130. Vetto JT, Lum S, Morris A et al.: Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J. Surg. 174, 258-265 (1997).
131. Petty JK, He K, Corless CL, Vetto JT, Weinberg AD: Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am. J.Surg. 183, 512-518 (2002). ■■ Clinical correlation of OX40 expression in the tumor microenvironment with prolonged survival.
132. Ladanyi A, Somlai B, Gilde K, Fejos Z, Gaudi I, Timar J: T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin. Cancer Res. 10, 521-530 (2004).
133. Weinberg AD, Thalhofer C, Morris N et al.: Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J. Immunother. 29, 575-585 (2006). (Pubitemid 44674041)
134. Morris NP, Peters C, Montier R et al.: Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. MoL Immunol. 44, 3112-3121 (2007). (Pubitemid 46610514)
135. Melero I, Hervas-Stubbs S, Glennie M et al.: Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7, 95-106 (2007).
136. + T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 13, 4345-4354 (2007).
137. Salih HR, Schmetzer HM, Burke C et al.: Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J. Immunol. 167, 4059-4066 (2001). (Pubitemid 32910853)
138. Kim YS, Jung HW, Choi J et al.: Expression of AlTR and AITR ligand in breast cancer patients. Oncol. Rep. 18, 1189-1194 (2007).
139. Baltz KM, Krusch M, Baessler T et al.: Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood 112, 3735-3743 (2008).
140. Baltz KM, Krusch M, Bringmann A et al.: Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEBJ. 21, 2442-2454 (2007). (Pubitemid 47230674)
141. Ponte J, Apostolou I, Doty D et al.: Characterization of a humanized anti-hGITR monoclonal antibody, TRX518. Presented at: International Society for Biological Therapy of Cancer 23rd Annual Meeting. San Diego, CA, USA, 31 October-2 November 2008.
142. Ndhlovu LC, Takeda I, Sugamura K et al.: Expanding role of T-cell costimulators in regulatory T-cell function: recent advances in accessory molecules expressed on both regulatory and nonregulatory T cells. Crit. Rev. Immunol. 24, 251-266 (2004).
143. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263-274 (2005).
144. Suntharalingam G, Perry MR, Ward S et al.: Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
145. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239 (2008).
146. Weber JS, O'Day S, Urba W et al.: Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. (2008).
147. Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836-848 (2006).
148. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL: 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol. 162, 5003-5010 (1999).
149. Wilcox RA, Flies DB, Zhu G et al.: Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109, 651-659 (2002).
150. Strome SE, Martin B, Flies D et al.: Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. J. Immunother. 23, 430-437 (2000).
151. Li Q Iuchi T, Jure-Kunkel MN, Chang AE: Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int. J. Biol. Sci. 3, 455-462 (2007).
152. Chen L, Huang TG, Meseck M et al.: Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol. Ther. 15, 2194-2202 (2007).
153. Dannull J, Nair S, Su Z et al.: Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105, 3206-3213 (2005). (Pubitemid 40504341)
154. Gri G, Gallo E, Di Carlo E, Musiani P, Colombo MP: OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-APC signaling to boost the host T cell antitumor response. J. Immunol. 170, 99-106 (2003).
155. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD: Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J. Immunol. 179, 7244-7253 (2007).
156. Houot R, Levy R: T cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood DOI: 0: blood-2008-07-170274v1 (2008) (Epub ahead of print).
157. Final rankings of agents with high potential for use in treating cancer, National Cancer Institute Immunotherapy Agent Workshop: 12 July (2007). http://dcb.nci.nih.gov/immunagentwork/final-rankings-of-agents-with-high- potential-for-use-in-treating-cancer.cfm